Related Experiment Videos
Fenofibrate in type IV and type V hyperlipoproteinemia
1Bristol-Myers US Pharmaceutical Group, Evansville, Ind.
Cardiology
|January 1, 1989
Summary
Fenofibrate effectively lowers triglyceride levels in patients with severe hyperlipoproteinemia types IV and V. This study found fenofibrate safe and effective, with minimal side effects for managing these lipid disorders.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Metabolic Disorders
Background:
- Hyperlipoproteinemia types IV and V are characterized by elevated triglyceride levels.
- Effective management of these lipid disorders is crucial for cardiovascular health.
Purpose of the Study:
- To evaluate the efficacy and safety of fenofibrate in patients with type IV or V hyperlipoproteinemia.
- To assess fenofibrate's impact on triglyceride, cholesterol, and lipoprotein levels.
Main Methods:
- A US multicenter, double-blind, placebo-controlled study.
- 147 patients with type IV or V hyperlipoproteinemia were randomized to fenofibrate or placebo after a low-fat diet stabilization.
- Patients were stratified by plasma triglyceride levels (350-499 mg/dl or 500-1,500 mg/dl).
Main Results:
- Fenofibrate significantly reduced total triglyceride levels by 46% (Group A) and 55% (Group B) within 2 weeks.
- Fenofibrate decreased very low-density lipoprotein (VLDL) triglycerides and cholesterol, and total cholesterol.
- High-density lipoprotein (HDL) levels were increased by fenofibrate treatment.
Conclusions:
- Fenofibrate is an effective treatment for type IV and V hyperlipoproteinemia.
- Fenofibrate demonstrated a favorable safety profile with minimal adverse effects compared to placebo.
- The drug's efficacy and safety profile support its use in managing these specific hyperlipoproteinemia types.